Monitor cash runway closely — $3.5M at current burn rate suggests need for additional financing within 1-2 quarters. Interim CYWC628 data in 2H 2026 is the key catalyst; any delay or negative readout would be highly bearish for the $4M market cap stock.
Price Chart
Executive Summary
FibroBiologics reported Q2 2026 EPS of -$0.66, beating consensus of -$0.93 by 29%, but remains pre-revenue with $3.5M cash. The company dosed its first patient in the Phase 1/2 CYWC628 trial for diabetic foot ulcers and expects interim data in 2H 2026. The EPS beat is on a tiny base and does not change the fundamental cash-burn story.
Key Financial Metrics
Key Facts
- EPS -$0.66 vs consensus -$0.93 (29% beat) on lower R&D expenses
- Revenue $0 (pre-revenue clinical-stage biotech)
- Cash and cash equivalents $3.5M at June 30, 2026
- Net loss $4.1M for Q2 2026
- First patient dosed in Phase 1/2 CYWC628 trial for diabetic foot ulcers
- Completed $9.0M private placement and $3.0M public offering
- Interim CYWC628 data expected 2H 2026; IND filings for psoriasis and MS planned Q4 2026
Financial Impact
EPS beat of 29% on a tiny base; cash burn rate ~$4.1M/quarter implies runway of less than one quarter without additional financing
Risk Factors
- Cash runway only ~1 quarter at current burn rate ($4.1M/quarter)
- Pre-revenue with no approved products; entirely dependent on clinical trial success
- Dilution risk from recent and future financings given low cash position
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302840401 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | EFFECT | $0.9199 | awaiting T+5 | — | $0.9221 (−0.24%) |
Oct 20, 2026 6d ago | EFFECT | $0.9199 | awaiting T+5 | — | $0.9221 (−0.24%) |
Oct 8, 2026 17d ago | 8-K | $1.13 $0.9710 | ▲ +14.07% | ▲ +12.10% | $0.9221 (+18.40%) |
Sep 15, 2026 5w ago | 8-K | $1.44 $1.43 | ▼ −0.69% | ▼ −1.51% | $0.9221 (−35.97%) |
Aug 24, 2026 9w ago | 8-K | $1.35 $1.72 | ▲ +27.41% | ▲ +26.94% | $0.9221 (−31.70%) |
Jul 31, 2026 12w ago | Press Release | $0.7910 $0.9800 | ▲ +23.89% | ▲ +21.87% | $0.9221 (+16.57%) |
Jul 17, 2026 14w ago | EFFECT | $0.8349 $0.7355 | ▲ +11.91% | ▲ +11.22% | $0.9221 (−10.44%) |
Jul 9, 2026 15w ago | 8-K | $0.8610 $0.8398 | ▼ −2.46% | ▼ −2.33% | $0.9221 (+7.10%) |
Jun 29, 2026 16w ago | 8-K | $0.9477 $0.8687 | ▲ +8.34% | ▲ +8.94% | $0.9221 (+2.70%) |
May 11, 2026 24w ago | Press Release | $0.9900 $1.09 | ▲ +10.10% | ▲ +10.19% | $0.9221 (−6.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers